Advertisements



Goldman says Bristol-Myers reaction to NSCLC data, Merck news "way overdone"

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol reaction to NSCLC data, Merck news "way overdone," says Goldman Sachs

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol-Myers announces CNDA approval of Opdivo for NSCLC treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Nektar, Bristol-Myers announce preliminary data from PIVOT Phase 1/2 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 3rd, 2018

Bristol-Myers reports patient-reported outcomes data from CheckMate-214 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 1st, 2018

Bristol-Myers downgraded on lung cancer data disappointment at Morgan Stanley

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 17th, 2018

Biotech Analysis Central Pharma News: Merck"s Keytruda Breakthrough, Bristol Myers And JNJ Team Up, Alkermes Gets A Second Shot

Biotech Analysis Central Pharma News: Merck"s Keytruda Breakthrough, Bristol Myers And JNJ Team Up, Alkermes Gets A Second Shot.....»»

Category: topSource: seekingalphaApr 17th, 2018

Merck Cements Lead in Lung Cancer as Bristol-Myers Fizzles

Merck & Co. might have just shut the door on rival Bristol-Myers Squibb Co. as investors weigh new data that could reshape the treatment of lung cancer, by far the deadliest form of cancer in the U.S......»»

Category: topSource: moneycentralApr 16th, 2018

Nektar shares drop 16% to $84.50 after Bristol-Myers cancer data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo

Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -0.....»»

Category: worldSource: nytApr 16th, 2018

Merck rises, Bristol-Myers slides following cancer meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Bristol-Myers enters new clinical collaboration with Vedanta Biosciences

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 10th, 2018

Bristol-Myers raises quarterly dividend 2.5% to 41c per share

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 6th, 2018

Bristol-Myers upgraded to Outperform at BMO Capital on better Opdivo sales

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 6th, 2018

Bristol-Myers upgraded to Outperform from Market Perform at BMO Capital

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 6th, 2018

Athene in significant pension risk transfer transaction with Bristol-Myers

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 3rd, 2018

Bristol-Myers to transfer $3.8B in U.S. pension liabilities

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 3rd, 2018

Bristol-Myers trial failure has minimal financial impact, says William Blair

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 27th, 2018

Bristol-Myers price target lowered to $56 at BMO Capital on execution concern

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 27th, 2018

Bristol-Myers down 2.3% after Phase 3 study misses primary endpoint

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 26th, 2018

Bristol-Myers Phase 3 CheckMate -451 study did not meet primary endpoint

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallNov 26th, 2018